Referral pattern for urologic malignancies before and during the COVID-19 pandemic

[1]  A. Purushotham,et al.  The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study , 2020, The Lancet Oncology.

[2]  J. Emery,et al.  Cancer has not gone away: A primary care perspective to support a balanced approach for timely cancer diagnosis during COVID‐19 , 2020, European journal of cancer care.

[3]  S. Tirumani,et al.  COVID-19 Pandemic Impact on Decreased Imaging Utilization: A Single Institutional Experience , 2020, Academic Radiology.

[4]  M. Staehler,et al.  Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? , 2020, European Urology Focus.

[5]  J. Olayiwola,et al.  Strategies for Digital Care of Vulnerable Patients in a COVID-19 World-Keeping in Touch. , 2020, JAMA health forum.

[6]  A. Banerjee,et al.  Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency , 2020, medRxiv.

[7]  A. Zureikat,et al.  Cancer disparities in the COVID‐19 era , 2020, Journal of surgical oncology.

[8]  B. Ebert,et al.  The impact of the COVID-19 pandemic on cancer care , 2020, Nature Cancer.

[9]  S. Duffy,et al.  Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care , 2020, The Lancet Oncology.

[10]  I. Nagtegaal,et al.  Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands , 2020, The Lancet Oncology.

[11]  N. Hale,et al.  The COVID-19 Catalyst: Analysis of a Tertiary Academic Institution’s Rapid Assimilation of Telemedicine , 2020, Urology Practice.

[12]  R. Fisher,et al.  A War on Two Fronts: Cancer Care in the Time of COVID-19 , 2020, Annals of Internal Medicine.